Brief: Successful Primary Engraftment Of Trem-cel In First Five AML Patients Demonstrates Promise Of Vor Bio's Platform
09/06/2023 12:38
June 9 (Reuters) - Vor Biopharma Inc VOR.O :
* SUCCESSFUL PRIMARY ENGRAFTMENT OF TREM-CEL IN FIRST FIVE
AML
PATIENTS DEMONSTRATES PROMISE OF VOR BIO’S PLATFORM
* VOR BIOPHARMA INC - ADDITIONAL DATA UPDATES EXPECTED BY
YEAR-END
2023
Source text for Eikon: ID:nGNX9nyrQC
Further company coverage: VOR.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Vor Biopharma
See all newsBrief: Telitacicept Demonstrates Durable Preservation Of Kidney Function Through Two Years In Phase 3 Teligan Trial In Iga Nephropathy
Vor Bio says its experimental drug slowed loss of kidney function in late-stage study
U.S. STOCKS ON THE MOVE-Vor Biopharma, Fair Isaac Corp, Plug Power
U.S. STOCKS ON THE MOVE-Snowflake, Cboe, Oracle
US STOCKS ON THE MOVE-Veracyte, Staar Surgical, Corning